TY - JOUR T1 - Rofecoxib caused fewer endoscopic gastroduodenal ulcers than ibuprofen in osteoarthritis JF - Evidence Based Medicine JO - Evid Based Med SP - 74 LP - 74 DO - 10.1136/ebm.5.3.74 VL - 5 IS - 3 A2 - , Y1 - 2000/05/01 UR - http://ebm.bmj.com/content/5/3/74.abstract N2 - (1999) Gastroenterology 117, 776. Laine L, Harper S, Simon T, et al,. for the Rofecoxib Osteoarthritis Endoscopy Study Group.. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis.. Oct;. :. –83.OpenUrlCrossRefPubMedWeb of Science
 
 QUESTION: In patients with osteoarthritis (OA), does rofecoxib at doses of 25 and 50 mg/day cause fewer endoscopic gastroduodenal ulcers than ibuprofen? Randomised (allocation concealed*), blinded (patients, clinicians, and outcome assessors),* placebo controlled trial with 24 week follow up. 33 clinical centres in the United States. 742 patients (mean age 62 y, 68% women, 83% white) ≥50 years of age with OA that had required non-steroidal anti-inflammatory drugs (NSAIDs) for ≥6 months. Exclusion criteria were active ulcers; inflammatory bowel disease; previous upper gastrointestinal (GI) surgery; pyloric obstruction; erosive oesophagitis; abnormal serum creatinine levels or clearance; faecal occult blood; unstable medical conditions; history of cancer or cerebrovascular events; bleeding diathesis; or need for anticoagulants, ticlopidine, corticosteroids, or aspirin. The intention to treat analysis included 93% of the patients. Patients were allocated to 16 to 24 weeks of rofecoxib, 25 mg/day (n=195); rofecoxib, 50 mg/day (n=186); ibuprofen, 2400 mg/day (n=184); or placebo (n=177). Some other drugs were allowed … ER -